An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients

NCT02560649 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

324

Enrollment

OTHER

Sponsor class

Conditions

Chronic Hepatitis B

Interventions

DRUG: Peginterferon alfa-2a plus Entecavir
DRUG: Peginterferon alfa-2a plus Lamivudine
DRUG: Peginterferon alfa-2a plus Adefovir
DRUG: Peginterferon alfa-2a plus Tenofovir
DRUG: Entecavir
DRUG: Lamivudine
DRUG: Adefovir
DRUG: Tenofovir disoproxil

Sponsor

Ruijin Hospital